Log in

NYSE:PFEPfizer Competitors & Alternatives

$33.83
+0.37 (+1.11 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$33.49
Now: $33.83
$34.04
50-Day Range
$32.04
MA: $34.86
$38.19
52-Week Range
$27.88
Now: $33.83
$43.56
Volume23.19 million shs
Average Volume30.67 million shs
Market Capitalization$187.92 billion
P/E Ratio12.08
Dividend Yield4.49%
Beta0.68

Competitors

Pfizer (NYSE:PFE) Vs. JNJ, MRK, LLY, ABBV, BMY, and ZTS

Should you be buying PFE stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Pfizer, including Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Zoetis (ZTS).

Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares Pfizer and Johnson & Johnson's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion3.63$16.27 billion$2.9511.47
Johnson & Johnson$82.06 billion4.57$15.12 billion$8.6816.40

Pfizer has higher earnings, but lower revenue than Johnson & Johnson. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Pfizer has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

Profitability

This table compares Pfizer and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer31.17%25.76%9.91%
Johnson & Johnson24.47%39.71%15.27%

Analyst Ratings

This is a breakdown of current ratings for Pfizer and Johnson & Johnson, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer08402.33
Johnson & Johnson041202.75

Pfizer currently has a consensus price target of $38.6083, indicating a potential upside of 14.12%. Johnson & Johnson has a consensus price target of $163.8571, indicating a potential upside of 15.09%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Pfizer.

Dividends

Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.5%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.8%. Pfizer pays out 51.5% of its earnings in the form of a dividend. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 10 consecutive years and Johnson & Johnson has increased its dividend for 57 consecutive years.

Insider & Institutional Ownership

70.2% of Pfizer shares are held by institutional investors. Comparatively, 68.4% of Johnson & Johnson shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Johnson & Johnson beats Pfizer on 13 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation & Earnings

This table compares Pfizer and Merck & Co., Inc.'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion3.63$16.27 billion$2.9511.47
Merck & Co., Inc.$46.84 billion4.13$9.84 billion$5.1914.78

Pfizer has higher revenue and earnings than Merck & Co., Inc.. Pfizer is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Pfizer has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.

Profitability

This table compares Pfizer and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer31.17%25.76%9.91%
Merck & Co., Inc.21.10%52.46%16.67%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Pfizer and Merck & Co., Inc., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer08402.33
Merck & Co., Inc.021102.85

Pfizer currently has a consensus price target of $38.6083, suggesting a potential upside of 14.12%. Merck & Co., Inc. has a consensus price target of $94.1538, suggesting a potential upside of 22.71%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Pfizer.

Dividends

Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.5%. Merck & Co., Inc. pays an annual dividend of $2.44 per share and has a dividend yield of 3.2%. Pfizer pays out 51.5% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 47.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 10 consecutive years and Merck & Co., Inc. has increased its dividend for 8 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

70.2% of Pfizer shares are owned by institutional investors. Comparatively, 74.3% of Merck & Co., Inc. shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Pfizer on 11 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Eli Lilly And Co (NYSE:LLY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation & Earnings

This table compares Pfizer and Eli Lilly And Co's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion3.63$16.27 billion$2.9511.47
Eli Lilly And Co$22.32 billion7.00$8.32 billion$6.0427.05

Pfizer has higher revenue and earnings than Eli Lilly And Co. Pfizer is trading at a lower price-to-earnings ratio than Eli Lilly And Co, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Pfizer has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Eli Lilly And Co has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.

Profitability

This table compares Pfizer and Eli Lilly And Co's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer31.17%25.76%9.91%
Eli Lilly And Co23.97%194.18%15.11%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Pfizer and Eli Lilly And Co, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer08402.33
Eli Lilly And Co04712.75

Pfizer currently has a consensus price target of $38.6083, suggesting a potential upside of 14.12%. Eli Lilly And Co has a consensus price target of $169.7273, suggesting a potential upside of 3.90%. Given Pfizer's higher probable upside, research analysts plainly believe Pfizer is more favorable than Eli Lilly And Co.

Dividends

Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.5%. Eli Lilly And Co pays an annual dividend of $2.96 per share and has a dividend yield of 1.8%. Pfizer pays out 51.5% of its earnings in the form of a dividend. Eli Lilly And Co pays out 49.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 10 consecutive years and Eli Lilly And Co has increased its dividend for 5 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

70.2% of Pfizer shares are owned by institutional investors. Comparatively, 77.3% of Eli Lilly And Co shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 0.1% of Eli Lilly And Co shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Eli Lilly And Co beats Pfizer on 11 of the 18 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Dividends

AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 4.9%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.5%. AbbVie pays out 52.8% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 47 consecutive years and Pfizer has increased its dividend for 10 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

72.4% of AbbVie shares are held by institutional investors. Comparatively, 70.2% of Pfizer shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares AbbVie and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie24.77%-169.80%18.52%
Pfizer31.17%25.76%9.91%

Analyst Recommendations

This is a summary of current ratings and target prices for AbbVie and Pfizer, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie031402.82
Pfizer08402.33

AbbVie currently has a consensus target price of $106.80, suggesting a potential upside of 10.30%. Pfizer has a consensus target price of $38.6083, suggesting a potential upside of 14.12%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than AbbVie.

Volatility & Risk

AbbVie has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Earnings and Valuation

This table compares AbbVie and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion4.30$7.88 billion$8.9410.83
Pfizer$51.75 billion3.63$16.27 billion$2.9511.47

Pfizer has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Pfizer on 11 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Bristol-Myers Squibb and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb3.08%30.06%10.96%
Pfizer31.17%25.76%9.91%

Risk and Volatility

Bristol-Myers Squibb has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Institutional & Insider Ownership

74.2% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 70.2% of Pfizer shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Bristol-Myers Squibb and Pfizer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031102.79
Pfizer08402.33

Bristol-Myers Squibb presently has a consensus target price of $68.1667, suggesting a potential upside of 18.70%. Pfizer has a consensus target price of $38.6083, suggesting a potential upside of 14.12%. Given Bristol-Myers Squibb's stronger consensus rating and higher possible upside, equities research analysts clearly believe Bristol-Myers Squibb is more favorable than Pfizer.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.80 per share and has a dividend yield of 3.1%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.5%. Bristol-Myers Squibb pays out 38.4% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 10 consecutive years and Pfizer has increased its dividend for 10 consecutive years.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion4.97$3.44 billion$4.6912.25
Pfizer$51.75 billion3.63$16.27 billion$2.9511.47

Pfizer has higher revenue and earnings than Bristol-Myers Squibb. Pfizer is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol-Myers Squibb beats Pfizer on 12 of the 16 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Pfizer and Zoetis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer08402.33
Zoetis06812.67

Pfizer presently has a consensus price target of $38.6083, suggesting a potential upside of 14.12%. Zoetis has a consensus price target of $142.3846, suggesting a potential upside of 3.85%. Given Pfizer's higher possible upside, analysts clearly believe Pfizer is more favorable than Zoetis.

Valuation and Earnings

This table compares Pfizer and Zoetis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion3.63$16.27 billion$2.9511.47
Zoetis$6.26 billion10.40$1.50 billion$3.6437.66

Pfizer has higher revenue and earnings than Zoetis. Pfizer is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Dividends

Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.5%. Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.6%. Pfizer pays out 51.5% of its earnings in the form of a dividend. Zoetis pays out 22.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 10 consecutive years and Zoetis has raised its dividend for 6 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility and Risk

Pfizer has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Profitability

This table compares Pfizer and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer31.17%25.76%9.91%
Zoetis25.41%67.72%15.76%

Insider and Institutional Ownership

70.2% of Pfizer shares are held by institutional investors. Comparatively, 91.5% of Zoetis shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Zoetis beats Pfizer on 12 of the 18 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.4$142.37+0.1%$375.09 billion$82.06 billion18.83Upcoming Earnings
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.3$76.73+0.1%$193.67 billion$46.84 billion19.43
Eli Lilly And Co logo
LLY
Eli Lilly And Co
2.0$163.36+1.9%$156.25 billion$22.32 billion27.00Insider Selling
AbbVie logo
ABBV
AbbVie
2.7$96.83+1.1%$142.99 billion$33.27 billion17.14
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.2$57.43+1.2%$129.95 billion$26.15 billion70.90
Zoetis logo
ZTS
Zoetis
1.9$137.10+0.4%$65.11 billion$6.26 billion40.93
Royalty Pharma logo
RPRX
Royalty Pharma
1.1$47.64+1.5%$28.36 billionN/A0.00Analyst Report
Horizon Therapeutics logo
HZNP
Horizon Therapeutics
1.7$57.23+1.3%$10.92 billion$1.30 billion20.22
Mylan logo
MYL
Mylan
1.6$16.10+1.4%$8.32 billion$11.50 billion134.18
Perrigo logo
PRGO
Perrigo
1.9$55.17+1.6%$7.52 billion$4.84 billion40.27
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
3.1$106.60+1.1%$5.90 billion$2.16 billion22.16
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.8$24.03+1.6%$4.28 billion$114.62 million-9.21Insider Selling
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.4$57.80+0.5%$2.43 billion$421.03 million-2,888.56Analyst Upgrade
Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.1$16.50+1.5%$1.89 billion$306.49 million18.75
Zogenix logo
ZGNX
Zogenix
2.0$27.24+2.1%$1.51 billion$3.65 million-2.89Analyst Downgrade
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.8$24.25+1.7%$1.27 billion$392.76 million11.18
Endo International logo
ENDP
Endo International
1.5$3.44+2.3%$790.18 million$2.91 billion-2.82
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.3$23.02+2.4%$753.27 million$15.96 million-6.71
Omeros logo
OMER
Omeros
1.5$13.61+1.5%$741.89 million$111.81 million-7.87
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
1.9$4.22+1.4%$422.70 million$111.39 million-46.89Heavy News Reporting
Lannett logo
LCI
Lannett
1.6$5.74+7.7%$231.61 million$655.41 million-7.00High Trading Volume
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$5.22+2.9%$225.15 million$16.54 million-1.50
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
2.4$3.18+0.6%$48.28 million$47.53 million-10.60
VIVUS logo
VVUS
VIVUS
1.2$0.53+7.5%$9.45 million$69.76 million-0.20
This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.